ArticleAmerican journal of clinical pathology2019
Breast Cancers With Magee Equation Score of Less Than 18, or 18-25 and Mitosis Score of 1, Do Not Require Oncotype DX Testing: A Value Study.
Article in American journal of clinical pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Tumour-infiltrating lymphocytes differ across MammaPrint® classifications in breast cancer.Endocrine-related cancer · 2026Article
- Article
- Financial De-Escalation in T1 Breast Cancers With the Low Magee Equation: An Experience From A Single Institution Without Genomic Testing.European journal of breast health · 2025Article
- A Simplified Novel Algorithm to Predict the 21-Gene Recurrence Score.World journal of oncology · 2025Article
- The Magee Equation: A Potential Economic Alternative in the Prognostication of Patients With Breast Cancer.Cureus · 2025Article
- Article
- A Multicenter Physician Survey Evaluating the Use of Ki-67 in Breast Cancer Management in Canada.Biomedicines · 2024Article
- Predictive and prognostic biomarkers in breast tumours.Pathology · 2024Review
- Article
- The Evolution of Ki-67 and Breast Carcinoma: Past Observations, Present Directions, and Future Considerations.Cancers · 2023Review
- Personalising therapy for early-stage oestrogen receptor-positive breast cancer in older women.The lancet. Healthy longevity · 2022Review
- Concordance between results of inexpensive statistical models and multigene signatures in patients with ER+/HER2- early breast cancer.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021Article
- Systematic evaluation of scoring methods for Ki67 as a surrogate for 21-gene recurrence score.NPJ breast cancer · 2021Article
- Magee Equations™ and response to neoadjuvant chemotherapy in ER+/HER2-negative breast cancer: a multi-institutional study.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021Article
- Prosigna® breast cancer assay: histopathologic correlation, development, and assessment of size, nodal status, Ki-67 (SiNK™) index for breast cancer prognosis.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021Article
- The healthcare value of the Magee Decision Algorithm™: use of Magee Equations™ and mitosis score to safely forgo molecular testing in breast cancer.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2020Article
- Risk stratification of ER-positive breast cancer patients: A multi-institutional validation and outcome study of the Rochester Modified Magee algorithm (RoMMa) and prediction of an Oncotype DXCancer medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To investigate use of Magee equations (MEs) to determine which breast cancer cases can be excluded from Oncotype DX testing. Methods: A prospective value study was carried out using data from pathology reports. Results: If all three MEs scores were less than 18 or 31 or higher, the cases were labeled do not send for testing. If any or all scores were 18 to 25, cases were labeled do not send if mitosis score was 1. Of the total 205 cases, 146 (71%) were labeled do not send; of these, the correct call was made in 143 (98%) cases. Two of the three discordant cases had associated nontumor factors, likely resulting in higher scores. Conclusions: Cases with ME scores less than 18, or 18 to 25 and mitosis score 1, do not require Oncotype DX testing, an estimated saving of US$280,000 per 100 clinical requests.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.